Ditchcarbon
  • Contact
  1. Organizations
  2. Menarini
Public Profile
Pharmaceutical Preparation Manufacturing
IT
updated a month ago

Menarini Sustainability Profile

Company website

Menarini Group, a prominent player in the pharmaceutical industry, is headquartered in Florence, Italy. Founded in 1886, the company has established a strong presence across Europe, Asia, and the Americas, focusing on research, development, and the manufacturing of innovative healthcare solutions. Specialising in prescription pharmaceuticals, over-the-counter products, and diagnostics, Menarini is recognised for its commitment to quality and patient care. The company’s core offerings include therapeutic areas such as oncology, cardiology, and infectious diseases, distinguished by their efficacy and safety profiles. With a rich history of milestones, Menarini has achieved significant market position, consistently ranking among the top pharmaceutical companies in Italy. Its dedication to advancing medical science and improving patient outcomes underscores its reputation as a trusted name in healthcare.

DitchCarbon Score

How does Menarini's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

23

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

34

Industry Benchmark

Menarini's score of 23 is lower than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.

27%

Let us know if this data was useful to you

Menarini's reported carbon emissions

In 2023, Menarini reported total carbon emissions of approximately 1,238,770 kg CO2e, comprising 100,390 kg CO2e from Scope 1, 26,250 kg CO2e from Scope 2, and 1,125,130 kg CO2e from Scope 3 emissions. This represents a slight decrease in total emissions compared to 2022, when the company recorded about 1,299,240 kg CO2e, with Scope 1 emissions at 47,200 kg CO2e, Scope 2 at 21,970 kg CO2e, and Scope 3 at 1,275,970 kg CO2e. Menarini has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company’s emissions data is not cascaded from a parent organization, indicating that these figures are independently reported. Overall, Menarini's commitment to addressing carbon emissions is evident through its transparency in reporting, although further details on reduction strategies would enhance its climate action profile.

How Carbon Intensive is Menarini's Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Menarini's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Menarini's Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Menarini is in IT, which has a low grid carbon intensity relative to other regions.

Menarini's Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Menarini has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Menarini's Emissions with Industry Peers

Johnson And Johnson

US
•
Pharmaceutical Preparation Manufacturing
Updated 17 days ago

Eli Lilly and Company

GB
•
Pharmaceutical Preparation Manufacturing
Updated about 19 hours ago

Natera

US
•
Research and development services (73)
Updated 3 days ago

Astra Zeneca

GB
•
Pharmaceutical Preparation Manufacturing
Updated 15 days ago

Arkopharma

FR
•
Pharmaceutical Preparation Manufacturing
Updated 17 days ago

Sanofi

FR
•
Pharmaceutical Preparation Manufacturing
Updated 5 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251118.2
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
Available onAWS Marketplace logo
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy